Intellectual Property
Arana’s patent position reflects the company’s focus on ensuring market exclusivity for lead therapeutic products in development. The company continues to pursue an aggressive policy of patenting discoveries and maximising patent coverage, with continual assessment of our own inventions and those of others in related areas that may impact on commercialisation of Arana’s products.
Arana’s current portfolio consists of 60 patent families with protection for its inventions being sought in major competitive markets including the U.S., Europe, Japan, Canada, Australia, China and India.
Arana scientists are aware of the importance of patents to the company and pay careful attention to the possibility of filing further applications as projects progress.
In the past 12 months, Arana has been granted some key patent rights for the protection of the following:
- PMX53 compound in Europe
- Use of PMX53 in the treatment of ulcerative colitis in
the U.S.
- ART101 in Australia
Patent families – income generation
Several of Arana’s patent families form the basis of the company’s income. Some of the patents listed below relate to anti-TNF (tumour necrosis factor), antibody humanisation by Superhumanisation™ and affinity maturation by EvoGene™ technologies.
|
 |
